Nanosynth Group PLC Successful Trial Results (6496X)
31 Agosto 2022 - 1:00AM
UK Regulatory
TIDMNNN
RNS Number : 6496X
Nanosynth Group PLC
31 August 2022
31 August 2022
nanosynth group plc
("nanosynth", the "Company" or the "Group")
Successful Trial Results
nanosynth, the AIM quoted company specialising in the synthesis
and application of nanoparticles to create new and improve existing
products, is pleased to announce successful trial results with Volz
Holdings v.o.s ("Volz") to enable both companies to develop a
standard retro-fit to media production lines, that allows for the
incorporation of the Company's antiviral technology into heating,
ventilation, and air conditioning ("HVAC")units.
With the completion of the latest trial production run, Volz is
now carrying out process improvements to enable more efficient and
consistent production of safe and reliable media for the end user.
The environmental impact of the treated media was evaluated and
determined to be classified as non-hazardous materials that can be
disposed of or recycled without restriction.
The UK's Health and Safety Executive ("HSE") has completed all
of its checks and has approved Pharm 2 Farm Limited ("P2F"), one of
the Company's subsidiaries , for REACH UK registration (UK
Registration, Evaluation, Authorisation and restriction of
Chemicals). The HSE has now allocated P2F to the appropriate
substance tonnage band, which will allow the production and
distribution of up to 100 tonnes of copper oxide nano-material per
year. This exceeds the Company's preliminary year one forecast
copper oxide nano-material sales requirements for the antiviral
HVAC market, enabling the Company to quickly expand into other
antipathogenic projects.
Mark Duffin, CEO of nanosynth commented: "We are delighted by
these extremely positive trial results and the important REACH UK
registration which will allow our partner, Volz, to apply our
antiviral technology to all of their products. This has the
potential to lead to wider adoption by the global filtration
industry. A pipeline of interest is already at an advanced stage,
and we are hopeful that this will lead to considerable sales for
our first to market antiviral product."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has
been incorporated into UK law by the European Union (Withdrawal)
Act 2018. Upon the publication of this announcement via Regulatory
Information Service ('RIS'), this inside is now considered to be in
the public domain.
ENQUIRIES :
nanosynth group plc via IFC Advisory
Mark Duffin (Chief Executive Officer)
SP Angel Corporate Finance LLP +44 20 3470 0470
Nominated Adviser and Broker
Stuart Gledhill
Caroline Rowe
IFC Advisory Ltd +44 20 3934 6630
Graham Herring
Zach Cohen
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSDEFISEESELA
(END) Dow Jones Newswires
August 31, 2022 02:00 ET (06:00 GMT)
Nanosynth (LSE:NNN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Nanosynth (LSE:NNN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024